New hope for tough childhood cancer: experimental drug targets aurora kinase
NCT ID NCT04106219
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental drug called LY3295668 erbumine in children whose neuroblastoma has returned or not responded to treatment. The study aims to find a safe dose and see if the drug can shrink tumors, either alone or with standard chemotherapy. About 71 participants will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3295668 erbumine (aurora kinase A inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for children with neuroblastoma that has come back or not responded to standard therapy.
What could go wrong
This is an early Phase 1 trial focused on safety, so it is too soon to know if the drug works. Side effects may be significant, and the drug may not shrink tumors in most participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alder Hey Children's Hospital
Liverpool, L14 5AB, United Kingdom
-
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, 69373 CEDEX 08, France
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Hospital Infantil Universitario Niño Jesús
Madrid, 28009, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], 8035, Spain
-
Institut Curie
Paris, 75248, France
-
Istituto Nazionale dei Tumori
Milan, Lombardy, 20133, Italy
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
Perth Children's Hospital
Perth, Western Australia, 6009, Australia
-
Texas Childrens Hospital
Houston, Texas, 77030, United States
-
UCSF Medical Center at Mission Bay
San Francisco, California, 94158, United States
-
UZ Gent
Ghent, Oost-Vlaanderen, 9000, Belgium
-
University of Chicago - Comer Children's Hospital
Chicago, Illinois, 60637, United States
-
Universitätsklinikum Köln
Cologne, 50924, Germany